These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1733189)

  • 1. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism.
    Konje JC; Otolorin EO; Ladipo OA
    Am J Obstet Gynecol; 1992 Jan; 166(1 Pt 1):15-9. PubMed ID: 1733189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive.
    Koopersmith TB; Lobo RA
    Contraception; 1995 Mar; 51(3):197-200. PubMed ID: 7621688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbohydrate metabolism before and after Norplant removal.
    Konje JC; Odukoya OA; Otolorin EO; Ewings PD; Ladipo OA
    Contraception; 1992 Jul; 46(1):61-9. PubMed ID: 1424624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system.
    Harper MA; Meis PJ; Steele L
    J Soc Gynecol Investig; 1997; 4(2):86-9. PubMed ID: 9101467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions.
    Shamma FN; Rossi G; HajHassan L; Penzias AS; Connoly-Diamond M; Jones E; Diamond MP
    Fertil Steril; 1995 Apr; 63(4):767-72. PubMed ID: 7890060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in carbohydrate metabolism during 30 months on Norplant.
    Konje JC; Otolorin EO; Ladipo OA
    Contraception; 1991 Aug; 44(2):163-72. PubMed ID: 1909945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal implants: contraception for a new century.
    Darney PD
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1536-43. PubMed ID: 8178903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implanon contraceptive implants: effects on carbohydrate metabolism.
    Biswas A; Viegas OA; Coeling Bennink HJ; Korver T; Ratnam SS
    Contraception; 2001 Mar; 63(3):137-41. PubMed ID: 11368985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subdermal progestin implant contraception.
    Darney PD
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of desogestrel on carbohydrate metabolism.
    Shoupe D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.
    Coukell AJ; Balfour JA
    Drugs; 1998 Jun; 55(6):861-87. PubMed ID: 9617600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel.
    Goodger AM; Rogers PA; Affandi B
    Hum Reprod; 1994 Sep; 9(9):1647-51. PubMed ID: 7530724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose metabolism among Norplant users in northern Nigeria.
    Sagay AS; Imade GE; Aisien AO; Ujah IO; Muazu MA
    Contraception; 2000 Jul; 62(1):19-22. PubMed ID: 11024224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate postpartum insertion of the norplant contraceptive device.
    Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
    Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norplant: subdermal implant system for long-term contraception.
    Shoupe D; Mishell DR
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1286-92. PubMed ID: 2497646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.